Table 2.
Completed phase III trials of antiangiogenic agents in gynecological cancers
| ID | Cancer/condition | No. | Intervention | mPFS (mon.) | mOS (mon.) | SAEs (%) | Refs |
|---|---|---|---|---|---|---|---|
| NCT00483782 ICON7 | OC/high-risk stage I–IIa, IIb–IV | 1528 | (1) PC | 17.5 | 58.6 | – | 37 |
| (2) PC + bevacizumab | 19.9, P = 0.25 | 58.0, P = 0.85 | – | ||||
| NCT00976911 AURELIA | OC/platinum-resistant recurrent | 361 | (1) Single-agent chemotherapy | 3.4 | 13.3 | 27.1 | 42 |
| (2) Chemotherapy + bevacizumab | 6.7, P < 0.001 | 16.6, P = 0.174 | 31.28 | ||||
| NCT00434642 OCEANS | OC/platinum-sensitive recurrent | 484 | (1) GC + placebo | 8.4 | 32.9 | 25.32 | 40 |
| (2) GC + bevacizumab | 12.4, P < 0.0001 | 33.6, P = 0.65 | 36.44 | ||||
| NCT00262847 GOG-0218 | OC/stage III–IV | 1873 | (1) PC + placebo | 10.3 | 41.1 | 38.49 | 35 |
| (2) PC + bevacizumab throughout | 14.1, P < 0.001 | 40.8, P = 0.34 | 41.19 | ||||
| (3) PC + bevacizumab combination only | 11.2, P = 0.16 | 43.4, P = 0.53 | 46.37 | ||||
| NCT00565851 GOG-0213 | OC/platinum-sensitive recurrent | 674 | (1) PC | 10.4 | 37.3 | 86 | 41 |
| (2) PC + bevacizumab | 13.8, P < 0·0001 | 42.2, P = 0.045 | 96 | ||||
| NCT00803062 GOG-0240 | CC/metastatic, persistent, or recurrent | 452 | (1) PC | 6 | 13.3 | 37.5 | 42,43 |
| (2) PT | 34.58 | ||||||
| (3) PC + bevacizumab | 47.75 | ||||||
| (4) PT + bevacizumab | 8.2, P = 0.002 | 16.8, P = 0.007 | 55.96 | ||||
| NCT00532194 ICON6 | OC/platinum-sensitive recurrent | 486 | (1) Chemotherapy + placebo | 8.7 | – | – | 73 |
| (2) Chemotherapy + cediranib throughout | 9.9 | – | |||||
| (3) Chemotherapy + cediranib combination only | 11, P < 0.0001 | – | |||||
| NCT01015118 AGO-OVAR12 | OC/stage IIb–IV | 1503 | (1) PC + placebo | 16.6 | 62.8 | 34.89 | 67 |
| (2) PC + nintedanib | 17.2, P = 0.24 | 62, P = 0.087 | 42.02 | ||||
| NCT00866697 AGO-OVR16 | OC/stage II–IV, after first-line chemotherapy | 940 | (1) Placebo | 12.3 | 64.0 | 11.06 | 63 |
| (2) Pazopanib | 17.9, P = 0.0021 | 59.1, P = 0.64 | 25.37 | ||||
| NCT01204749 TRINOVA-1 | OC/recurrent | 919 | (1) Paclitaxel + placebo | 5.4 | 17.3 | 52 | 78 |
| (2) Paclitaxel + trebananib | 7.2, P < 0.0001 | 19.0, P = 0.19 | 53 | ||||
| NCT01281254 TRINOVA-2 | OC/recurrent | 223 | (1) PLD + placebo | 7.2 | 17.0 | 72 | 81 |
| (2) PLD + trebananib | 7.6, P = 0.57 | 19.4, P = 0.76 | 73 | ||||
| NCT01493505 TRINOVA-3 | OC/stage III–IV | 1164 | (1) PC + placebo | 15.0 | – | 66 | 80 |
| (2) PC + trebananib | 15.9, P = 0.36 | 73 |
ID identifier, No. enrollment number, mPFS median progression-free survival, mOS median overall survival, Mon. months, SAEs serious adverse events, Refs references, Stage FIGO stage, PC paclitaxel + carboplatin, GC gemcitabine + carboplatin, PT topotecan + paclitaxel, PLD pegylated liposomal doxorubicin